Study Summary
This trial will test whether a new chemotherapy agent is effective and safe in treating brain metastases from triple negative breast cancer.
- Breast Cancer
- Metastatic Brain Tumors
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
2 Primary · 4 Secondary · Reporting Duration: 6 months
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
1 Treatment Group
QBS72S 12 mg/m2 IV injection
1 of 1
Experimental Treatment
40 Total Participants · 1 Treatment Group
Primary Treatment: QBS72S · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 0 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
How hazardous is QBS72S to human health?
"There is limited evidence suggesting QBS72S's safety, giving it a rating of 2. However, there are no findings to support the drug's efficacy yet." - Anonymous Online Contributor
How many participants are involved in the current clinical research?
"Yes, the information hosted on clinicaltrials.gov confirms that this medical trial is actively engaging patients; it was initially posted on August 16th 2022 and its most recent update took place October 13th of that same year. The study requires 35 participants to be sourced from a single site." - Anonymous Online Contributor
Are there any vacancies available for this clinical experiment?
"The clinical trial is currently open to applicants, as referenced on the official website. This study was initially posted in August of 2022 and underwent its most recent update earlier this month." - Anonymous Online Contributor